Full Press Release Details
InspireMD Announces MGuard Prime
BOSTON, MA - April 27, 2015 - InspireMD,
Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in stent embolic protection systems ("EPS"),
today announced it received approval to commercialize MGuard Prime with MicroNet technology in Brazil. The approval was
granted by the Ag ncia Nacional de Vigil ncia Sanit ria (ANVISA). The BRICCS (Brazil, Russia, India, China,
South Africa and South Korea) coronary stents sector is estimated to reach $1billion by 2016, growing at an average compound annual
rate of 9.6% in 2012 to 2018, according to Research and Markets.
Alan Milinazzo, CEO of InspireMD, commented, "Brazil is
the largest Latin American coronary stent market with a rapidly aging population, growing economy, and improving healthcare system,
fueling coronary stenting procedure volumes." Mr. Milinazzo also added, "Approval of the MGuard Prime is significant
as we look to return to revenue growth as Brazil has traditionally been a very strong market for us with support from a number
of leading interventional cardiologists around the country."
Dr. Alex Abizaid, Chief of Coronary Interventions at Institute
Dante Pazzanese de Cardiologia in S o Paulo, Brazil, commented, "I am gratified that MGuard Prime is now approved
and available to treat STEMI patients in Brazil. Clinical trials and registry studies have provided a substantial body of evidence
supporting the use of MGuard in primary PCI with the objective of improving patient outcomes. With MGuard Prime, the treatment
of acute MI has reached a new level involving a simple device that can be used in daily practice in the cardiac cath laboratory."
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary
MGuard with MicroNet technology to make its products the industry standard for embolic protection and to provide a superior
solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major
adverse cardiac events.
InspireMD intends to pursue applications
of this MicroNet technology in coronary, carotid (CGuard ) and peripheral artery procedures. InspireMD's common stock
is quoted on the NYSE MKT under the ticker symbol NSPR.
Forward-looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks
and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results
or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi)
product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient
or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain
and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory
reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product
components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that
such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign
jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and
costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about
the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future
events or otherwise.
Chief Financial Officer
Phone: 1-888-776-6804
Email: craigs@inspiremd.com
Phone: (212) 554-5482